Revolution Medicines (RVMD) Research & Development (2019 - 2026)

Revolution Medicines' Research & Development history runs 8 years deep, the most recent figure standing at $344.0 million for Q1 2026.

• In Q1 2026, Research & Development rose 67.18% year-over-year to $344.0 million; the TTM figure through Mar 2026 stood at $1.1 billion (up 65.39% YoY), while the FY2025 annual figure was $987.3 million, up 66.72% from the prior year.
• Research & Development for Q1 2026 stood at $344.0 million, up from $294.9 million in the prior quarter.
• The five-year high for Research & Development was $344.0 million in Q1 2026, with the low at $56.5 million in Q1 2022.
• The 5-year median for Research & Development is $134.9 million (2024), against an average of $153.0 million.
• Peak annual rise in Research & Development reached 124.54% in 2023, while the deepest fall reached 22.05% in 2023.
• Revolution Medicines' Research & Development stood at $66.1 million in 2022, then soared by 124.54% to $148.5 million in 2023, then gained by 26.68% to $188.1 million in 2024, then surged by 56.8% to $294.9 million in 2025, then climbed by 16.62% to $344.0 million in 2026.
• Business Quant data shows RVMD's Research & Development at $344.0 million in Q1 2026, $294.9 million in Q4 2025, and $262.5 million in Q3 2025.